Dyax (DYAX) GF Value Rank : 0 (As of May. 05, 2024)

View and export this data going back to . Start your Free Trial

What is Dyax GF Value Rank?

Dyax has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Dyax GF Value Rank Related Terms

Thank you for viewing the detailed overview of Dyax's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyax (DYAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyax Corp (NAS:DYAX) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.dyax.com

Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.

Executives

David J Mclachlan	other: Former director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Gustav Christensen	officer: CEO and President, other: Former director	DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Todd Bazemore	officer: EVP & Chief Commercial Officer	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Thomas L Kempner	other: Former director	C/O LOEB PARTNERS CORPORATION, 125 BROAD STREET, 14TH FLOOR, NEW YORK NY 10004
Abbie Celniker	other: Former director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Marc D Kozin	other: Former director
Andrew D. Ashe	officer: General Counsel & EVP	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ron Cohen	other: Former director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Mary Ann Gray	other: Former director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
George V Migausky	officer: EVP & Chief Financial Officer	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Pucci	other: Former director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Burt A Adelman	officer: CMO & EVP, R&D	DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Ivana Magovcevic-liebisch	officer: EVP; Chief Operating Officer	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Susan B Bayh	director	WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Stephen S Galliker	officer: EVP and CFO	300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139